Mesothelioma Cancer Information

In the new economy, a steady, predictable income stream is a real asset – particularly if it is tax-free. Therefore, you should not be in too much of a hurry to sell your structured settlement unless the need is great – or there is a business opportunity that is too good to pass up.

Of course, you do not have to sell your entire structured settlement, and often, selling just a part of it can be the best solution all around.

There are no hard-and-fast rules to determine just how much of your structured settlement you should sell. Much of it depends on your individual circumstances and financial goals. You should look at your needs or purpose in selling, consider how much you will need to cover ongoing living expenses – then sell the smallest portion possible. The account representatives at the factoring company should be able to provide you with a variety of options so you can chose the transaction that fits your needs. At CBC we specialize in customized solutions to fit your specific needs.

http://www.seedol.com

As with anything else in life, there are up sides and downsides when selling your structured settlement or annuity payments. If you are considering doing this, it’s best to consider all aspects of the transaction and how it will affect your life and your finances.

The primary advantage of holding on to your structured payments lies in the security of having a steady stream of income.

This said, there are circumstances under which it is advantageous to take a lump sum payout. This can allow you to make a large purchase (such as a house) or investment without incurring debt. If you have a large amount of high interest credit card debt, having a lump sum of cash to pay it off with is often preferred.  Another reason to take a lump sum payout is if you are elderly and/or in poor health and have a reduced life expectancy (although under some circumstances, such payments can be left to an heir).

The primary downside is that when you cash in your structured settlement payments for a lump sum, you will receive less than the future value. However, in an inflationary economy, this disadvantage is offset somewhat when you consider that the lump sum dollars you get today are worth more than the structured payment amounts you would be getting in twenty years or so.

Another thing to keep in mind is that while your settlement remains tax-exempt, if you take that lump sum cash for settlement and create a new stream of income with it through an investment – say for example you use the funds to purchase rental property – the new source of income may be  taxable, as does any interest that is earned.  It is always recommended that you consult with your tax or other professional advisor regarding financial transactions.

http://www.seedol.com

It seems that every day, more and more advertisements or websites for the same products and services are appearing on the Internet.  The abundance of options might appear to be a benefit to consumers, but a closer look reveals that more players may only result in unnecessary confusion.  Some advertisements are for legitimate structured settlement companies while others are simply marketing machines trying to capture your personal information only to sell it to the highest bidder.

In an effort to approve this theory, I dove deep into the ever growing collection of structured settlement advertisements.  What I found was a number of structured settlement companies (such as CBC Settlement Funding) with real locations, people and resources to actually complete structured settlement transactions. What I also found was disturbing:  Dozens of websites that appear to be nothing more than marketing companies or alter egos of other entities that do not appear to have actual structured settlement employees, locations or the financial backing to actually complete the transactions they are soliciting.

How to tell the real companies from the marketing shams?

A few simple steps will allow consumers to differentiate between structured settlement companies that can actually purchase your structured settlement for a lump sum and those that are really just trying to get your information and sell it to the highest bidder.  Ask the following questions:

1. Does the website or advertisement list a physical address for the company?   This may seem obvious but believe it or not, many of these websites are not actual companies.  If there is a physical office location, this will help you determine whether you are dealing with a company or a scammer.
2. Does the website or advertisement identify how long the company has been in business?  Generally, if the website just recently appeared, you may be dealing with a scam operation.  If you call, be sure to ask how long the company has been in business or how many years of experience they have.  You can also verify a company’s history by visiting the Secretary of State website in the state the entity was formed.
3. Does the website for the company have a privacy policy?  A privacy policy identifies what a company will and will not do with information collected about consumers.  If the company has a privacy policy, read it, and find out what is in store for your personal information.  If the company does not have a privacy policy, run.

This is not by any means a complete discussion of how to tell a marketing machine scam from a trusted and established company.  Additional information will appear in future postings.

http://www.seedol.com

This generally depends on the nature of the structured settlement. If it is initially set up to compensate the recipient for the duration of his or her natural life, then naturally these payments would end with the passing of the measuring life.

Obviously, this is the preference of defendants in personal injury lawsuits, since their liability goes away once the plaintiff is dead. However, in most personal injury cases, there are often dependent family members to think about – particularly if the injury in question limits the plaintiff’s ability to work.

In some cases, a structured settlement may be period certain. This means that the payments continue for a fixed period of time, regardless of whether or not the recipient survives. If the recipient dies before the end of the period, the remaining payments either go the named beneficiaries or the estate.

Structured settlements may also be set up for what is known as joint and survivor benefit.  With this type of arrangement, payments continue to a specified person (“survivor”) upon the death of the primary beneficiary until the term of the settlement is complete.

If you are receiving payments from a structured settlement and are thinking about final arrangements, it’s a good idea to have a discussion with your attorney or tax professional. Selling structured settlements for a lump sum may be a good idea or not, depending on the nature of the agreement. Keep in mind that if your payments are for period certain, those payments will remain tax-exempt for your heirs, whereas any investment income or interest generated from a lump sum will be subject to income tax.

http://www.seedol.com

Even with a sizable legal settlement, with the nature of the unique profit-driven medical care system in the U.S. and its ever increasing costs to patients, it is still possible for a plaintiff who has been severely injured in an accident or due to a defective product to wind up in bankruptcy court. In fact, medical bills are the primary cause of bankruptcy in the United States, and it is the only industrialized nation in which this state of affairs exists and continues to be tolerated.

Unfortunately, for ordinary working people who run into such situations through no fault of their own, bankruptcy courts are not merciful. Since the reform laws passed by Congress in 2005, most people are forced into Chapter 13; they may keep most assets, but secured debts cannot be discharged. Instead, they are required to undergo credit counseling at their own expense and must follow a strict payment plan for five years – even when the bankruptcy was due not to overspending and carelessness but rather to medical bills.

Under Chapter 7 – for which qualification by working people is difficult – you may find relief, but only after you have surrendered all of your assets.

That’s the bad news.

The good news is that under the applicable laws, a structured settlement may be an exempt asset during bankruptcy proceedings. Though other personal assets may be subject to claims of creditors, your payments may be protected and remain intact.  As always consult your legal or tax professional for specific information in your jurisdiction.

However – if you sell your structured settlement for a lump sum, it’s fair game.

If you are in bankruptcy proceedings and have not yet been discharged, you or your trustee may still be able to sell your structured settlement; however, because of the additional legal work required, there may be additional delays.  Furthermore, it may not be a good idea, particularly if you are in a Chapter 7 proceeding. Once you have been stripped of everything else, that steady income may be invaluable in helping you to restart your life.

http://www.seedol.com

More information on Gardasil Miscarriage:

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.
2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Gardasil Miscarriage:

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

For Continued information on Gardasil Miscarriage

More (12/21/11) on Gardasil Miscarriage:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More relevant Information for Gardasil Miscarriage

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.
• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.
• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.
• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.
• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

For Continued Updates on Gardasil Miscarriage

http://www.seedol.com

More information on Gardasil Paralysis

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.

2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Gardasil Paralysis:

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

For Continued information on Gardasil Paralysis

More (12/21/11) on Gardasil Paralysis:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More relevant Information for Gardasil Paralysis

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.

• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.

• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.

• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.

• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

For Continued Updates on Gardasil Paralysis

http://www.seedol.com

Actos Class Action Lawsuit: There are both short-term and long-term complications associated with urinary diversion. In the immediate post­operative period, urine can leak from the site where the ureters were sewn into the bowel. This is generally self- limiting and heals on its own several days to a week after surgery. Very rarely is any intervention required. If you do have a urine leak after surgery, your physician will likely monitor this by the output of your drains that were placed at the time of the operation. When the drain output decreases, this is a sign that the leak has healed. The majority oflong-term complications patients experience after cystectomy are related to the urinary diversion. In fact, 10-20 percent of patients will need an additional procedure at some point over their lifetime to correct a problem with the urinary diversion. Over time, scar tissue can form at the site where the ureters were attached to the bowel, narrowing the lumen (cavity of the tube) that urine drains through. This is called a stricture. If a stricture occurs, it can inhibit the drainage of urine from the kidney, causing an obstruction. If this happens to you, you may feel pain in your back similar to that of a kidney stone, but some patients have no symptoms whatsoever if the stricture occurs slowly over time.

Your physician will periodically evaluate your kidneys with CTs or ultrasound to ensure proper drainage. Treatment for anastomotic strictures involves opening up this narrowed area to its previous size to allow the normal flow of urine into the ileal conduit or urinary reservoir. This can often be accomplished endoscopically without intra-abdominal surgery, but if such conservative measures fail, open surgery with anastomotic revision may be warranted. Fortunately, anas­tomotic strictures only occur in 3-7 percent of patients, and open surgery for such strictures is even rarer.

For more information on Actos Class Action Lawsuit follow us on our RSS Feeds.

Similarly to the narrowing that can occur at the connection between the ureters and the bowel, patients with ileal conduits can experience narrowing of the stoma at the level of the skin, which can impede the drainage of urine into the bag. This is known as stomal stenosis. Although this can be managed in the short term by simply placing a catheter into the stoma to allow drainage of urine, a surgical proce­dure is often necessary to revise the stoma. This procedure can generally be done on an outpatient basis.

There are several long-term complications specifically related to the fact that urine comes in contact with the intestinal portion of the diversion. Metabolic complications, such as acidosis, can occur but are often not clinically significant. The risk for clinically significant acidosis is higher in patients with continent urinary diversion because there is more intestinal surface area that comes in contact with the urine. Your physician will periodically monitor you for metabolic changes simply by checking lab tests. The majority of metabolic disturbances can be treated with dietary supplementation. Five to 10 percent of patients with urinary diversion form urinary stones at some point in their life, and approximately the same number experience repeated bouts of urinary tract infection or pyelonephritis.

Information from other sources on Actos Class Action Lawsuit

Continent urinary diversions have several complications that are unique compared with that of the ileal conduit. Patients with continent catheterizable diversion over time can experience leakage of urine from their catheterizable channel. Scar tissue can also form at the site of the cath­eterizable channel, causing difficulty with catheterization. Both problems generally require a secondary procedure to revise this portion of the diversion. Men and women with orthotopic urinary reconstructions can experience both urinary incontinence and urinary retention. The incidence of incontinence is greater in men than in women, but the incidence of urinary retention is greater in women. Urinary retention is often managed with clean intermittent catheterization, which consists of self-passage of a urinary catheter via the urethra several times a day to empty the diversion. If the idea of self-catheterization is unpalatable to you, this is something you should keep in mind when considering your choice of urinary diversion.

Our use of the term or terms Actos Class Action is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Class Action Lawsuit visit our site often.

http://www.seedol.com